Sponsors (10)
The bill increases safety and transparency around infant formula—speeding detection, traceability, and oversight to protect infants and help prevent shortages—at the cost of greater regulatory and reporting burdens on manufacturers and the FDA, with potential short-term supply disruptions and increased costs for businesses, agencies, or taxpayers.
Parents and infants: mandatory rapid reporting (within 1 business day), required provision of isolates/whole-genome data and FDA confirmation authority (including consultation and stop/dispose powers) speed investigations and reduce the time contaminated formula is distributed, lowering the risk of wider outbreaks.
Parents (especially low-income households) and policymakers: regular, detailed FDA supply and safety reporting (initial progress and supply reports, quarterly supply-chain data including in-stock rates for five years, and multi-year reviews) increases transparency and helps detect and respond to shortages earlier.
Public health systems and parents: directing the FDA to identify evidence-based manufacturer practices (testing frequency, bracketing, corrective actions) promotes safer production practices that could reduce contamination risk over time.
FDA staff, manufacturers, and regulated entities: the bill's tight timelines and expanded reporting/response duties will strain FDA resources and staff, risking rushed or inconsistent determinations and diverting agency capacity from other inspections or activities.
Manufacturers (particularly small businesses) and consumers: stricter rapid-reporting, mandatory data sharing, and disposal responsibilities raise compliance costs and operational disruption, which could increase formula prices or reduce supply stability.
Parents and infants: mandatory cessation and disposal of suspected product can cause temporary local shortages or reduced availability while affected inventory is removed, creating short-term access problems.
Based on analysis of 3 sections of legislative text.
Requires one-business-day FDA notification and rapid data sharing and distribution stoppage after confirmed microbial positives in infant formula, and mandates repeated FDA supply/safety reports.
Introduced January 28, 2025 by Gary C. Peters · Last progress May 4, 2026
Requires infant formula makers to notify FDA within one business day of any confirmed positive microbial test, stop distribution and work with FDA on disposal and corrective actions, and share test results or genetic data; requires FDA to begin investigation discussions within one business day and to confirm corrective action within 90 days. Also directs FDA to produce a series of reports and to consult with other agencies and stakeholders on infant formula safety and supply resilience, including regular supply-chain reports for five years and multi-year assessments of best practices.